Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors

William C. Patt, Harriet W. Hamilton(Pfizer (United States)), Michael D. Taylor(Pfizer (United States)), Michael J. Ryan(Pfizer (United States)), David G. Taylor(Pfizer (United States)), Cleo J. C. Connolly(Pfizer (United States)), Annette M. Doherty(Pfizer (United States)), S. KLUTCHKO(Pfizer (United States)), Ila Sircar(Pfizer (United States))
Journal of Medicinal Chemistry
July 1, 1992
Cited by 372Open Access
Full Text

Abstract

A series of renin inhibitors was synthesized that contained a 2-amino-4-thiazolyl moiety at the P2 position. These derivatives are potent inhibitors of monkey renin in vitro and are selective in that they only weakly inhibit the closely related aspartic proteinase, bovine cathepsin D. Four compounds exhibited oral blood pressure lowering activity in high-renin normotensive monkeys. One of these compounds, 22 (PD 134672), was selected for further evaluation in renal hypertensive monkeys, on the basis of its superior efficacy and duration of action in the in vitro assays and the normotensive primate model.


Related Papers

No related papers found

Powered by citation graph analysis